Trial · NCT01218477
Results by group79
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 79
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended Phase 2 Dose (RP2D) of BMS-833923 Plus Dasatinib in Chronic Myeloid Leukemia-Chronic Phase | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | 50 | mg | ||
| Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-CP with imatinib or nilo resistance/SOR (n=6) | 66.7 | 95% Confidence Interval 22.28 to 95.67 | Percentage of participants |
| Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-CP with dasatinib resistance/SOR (n=10) | 20 | 95% Confidence Interval 2.52 to 55.61 | Percentage of participants |
| Percentage of Participants With a Major Cytogenetic Response (MCyR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-Adv with imatinib or nilo resistance/SOR (n=3) | 66.7 | 95% Confidence Interval 9.43 to 99.16 | Percentage of participants |
| Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-CP with imatinib or nilo resistance/SOR (n=2) | 50 | 95% Confidence Interval 1.26 to 98.74 | Percentage of participants |
| Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-CP with dasatinib resistance/SOR (n=5) | 60 | 95% Confidence Interval 14.66 to 94.73 | Percentage of participants |
| Percentage of Participants With a Major Hematologic Response (MHR) in Chronic Myeloid Leukemia-Advanced Phase (CML-Adv) and Chronic Myeloid Leukemia-Chronic Phase (CML-CP) | Dasatinib, 100/140 mg QD, Plus BMS-833923, 50-200 BID/QD | CML-CP with imatinib or nilo resistance/SOR (n=1) | 100 | 95% Confidence Interval 2.5 to 100 | Percentage of participants |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD | Death | 1 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD | Death | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD | Death | 2 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD | Death | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD | SAEs | 1 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD | SAEs | 3 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD | SAEs | 5 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD | SAEs | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD | Drug-related SAEs | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD | Drug-related SAEs | 1 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD | Drug-related SAEs | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD | Drug-related SAEs | 0 | Participants | |
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Drug-related AEs Leading to Discontinuation, at Least 1 Drug-related AE, and Dose-limiting Toxicities | Dasatinib, 100/140 mg QD | AEs leading to discontinuation | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01218477/results